Janney Capital Starts uniQure BV (QURE) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Janney Capital Starts uniQure BV (QURE) at Buy
December 1, 2015 10:04 AM EST
Chardan Capital affirms its Buy rating and $40 price target on uniQure N.V. (Nasdaq: QURE) following the company's Q3 report and update issued on Monday.
Analyst Gbola Amusa says investors should buy on post-Q3 weakness. The analyst noted the following key points from the company's quarterly conference call:
AMT-060 (hemophilia B): In early January 2016 (previously due by end-2015), uniQure will release preliminary, top-line data for 2 patients who have completed at least 12 weeks of treatment, with full results from the first cohort of 5 patients at a scientific conference...
More
December 1, 2015 9:49 AM EST
Jefferies analyst, Eun Yang, reduced the price target on uniQure BV (NASDAQ: QURE) to $36 vs $40 previously. The drop takes into account the loss of revenue from the removal of Glybera and increasing the discount rate to 13% (from 12%) to reflect yet-to-be proven commercial potential/success of gene therapy products. No change to... More
December 1, 2015 7:11 AM EST
Oppenheimer Christopher Marai views yesterday's nearly 17% sell-off in uniQure BV (NASDAQ: QURE) unfounded. As such, the firm reiterated an Outperform rating and price target of $50.
uniQure reported 3Q15, ending the quarter with $215M in cash.
Marai commented, "Importantly, QURE clarified the... More
